Leadman(SZ:300289) Xin Lang Cai Jing·2025-10-15 02:03Core Viewpoint - Lidman has shown a significant stock price increase of 54.29% year-to-date, with recent fluctuations indicating a mixed performance in the short term [2]. Group 1: Stock Performance - As of October 15, Lidman’s stock price rose by 2.02% to 7.56 CNY per share, with a total market capitalization of 4.113 billion CNY [1]. - The stock has experienced a slight increase of 0.13% over the last five trading days, a decline of 4.91% over the last 20 days, and a substantial increase of 40.78% over the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Lidman reported a revenue of 160 million CNY, reflecting a year-on-year decrease of 14.80%, and a net profit attributable to shareholders of -4.2452 million CNY, a significant decline of 800.43% [3]. - The company has distributed a total of 143 million CNY in dividends since its A-share listing, with 5.4401 million CNY distributed over the last three years [4]. Group 3: Shareholder Information - As of September 30, the number of shareholders for Lidman was 32,900, a decrease of 1.79% from the previous period, while the average circulating shares per person increased by 1.82% to 16,487 shares [3]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund increased its holdings by 424,900 shares, while Hua Xia Zhong Zheng 500 Index Enhanced A became a new shareholder with 2,200,700 shares [4]. Group 4: Business Overview - Lidman, established on November 5, 1997, and listed on February 16, 2012, specializes in in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials, with the majority of revenue (67.84%) coming from in vitro diagnostic reagents [3]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and in vitro diagnostic sectors, and is involved in various concept sectors including gene sequencing and cold chain logistics [3].